Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.50 |
| ▸ | HMGCR | P04035 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7991151 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL10948997 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL4431565 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL158129 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3863172 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3858612 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL10948772 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL154493 | 0.97 | PTPN7 (0.46) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL10900975 | 0.90 | PTPN7 (0.53) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL14759549 | 0.90 | HMGCR (0.53) | PTPN7HMGCRRECQLTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756271-B1 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES | CSIR (ZA) | 2015-12-09 | — | — | EP | disclosed |
| EP-1753862-B1 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES | CSIR (ZA) | 2015-11-18 | — | — | EP | disclosed |
| US-7591995-B2 | Cobalamin conjugates useful as imaging and therapeutic agents | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090060837-A1 | COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS | COLLINS DOUGLAS A | 2009-03-05 | — | — | US | disclosed |
| US-7468432-B2 | Cobalamin conjugates useful as antitumor agents | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080286832-A1 | Methods for Obtaining Optically Active Epoxides and Vicinal Diols From 2,2-Disubstituted Epoxides | COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH (ZA) | 2008-11-20 | — | — | US | disclosed |
| WO-2008136850-A2 | COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080213833-A1 | Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates | OXRANE (UK) LTD. (GB) | 2008-09-04 | — | — | US | disclosed |
| US-20080199912-A1 | Methods for Obtaining Optically Active Epoxides and Diols from 2,3-Disubstituted and 2,3-Trisubstituted Epoxides | OXYRANE (UK) LTD. (GB) | 2008-08-21 | — | — | US | disclosed |
| EP-1896597-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND DIOLS FROM 2,3-DISUBSTITUTED AND 2,3-TRISUBSTITUTED EPOXIDES | CSIR (ZA) | 2008-03-12 | — | — | EP | disclosed |
| US-6284784-B1 | 2-HYDROXYMETHYL DERIVATIVES | GEORGETOWN UNIVERSITY | 2001-09-04 | — | — | US | disclosed |
| WO-2001028595-A1 | COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001002413-A1 | BAFIlOMYCIN DERIVATIVES WITH ANTICANCER ACTIVITY | INSTITUTO BIOMAR S.A. (ES) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000062808-A2 | COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1015427-A1 | SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC | GEORGETOWN UNIVERSITY (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0727473-B1 | Liquid crystaline alkynyltolan compound, liquid crystal composition and liquid crystal display element | CHISSO CORP (JP) | 2000-01-12 | — | — | EP | disclosed |
| US-5962504-A | ACTIVATOR OF PROTEIN KINASE; ANTICANCER AGENT | GEORGETOWN UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999012901-A1 | SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC | GEORGETOWN UNIVERSITY (US) | 1999-03-18 | — | — | WO | disclosed |
| US-5833879-A | LOW TEMPERATURE MISCIBILITY AND COMPATIBILITY WITH OTHER LIQUID CRYSTAL COMPOUNDS; DISPLAYS CONTAINING MIXTURES OF AT LEAST TWO COMPOUNDS, PHYSICAL PROPERTIES | CHISSO CORPORATION (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0727473-A2 | Liquid crystaline alkynyltolan compound, liquid crystal composition and liquid crystal display element | Chisso Corporation (JP) | 1996-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199912-A1 | Methods for Obtaining Optically Active Epoxides and Diols from 2,3-Disubstituted and 2,3-Trisubstituted Epoxides | EPHX2, ERG28, EPHX1 | PTPN7 4861/4885HMGCR 1301/4885RECQL 461/4885 |
| US-20090060837-A1 | COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS | MMAB, SLC19A2, SLC19A1 | PTPN7 4190/4885HMGCR 760/4885RECQL 902/4885 |
| US-20080213833-A1 | Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates | GALE, DERA, GNE | PTPN7 4402/4885HMGCR 1834/4885RECQL 1971/4885 |
| US-20080286832-A1 | Methods for Obtaining Optically Active Epoxides and Vicinal Diols From 2,2-Disubstituted Epoxides | EPHX2, ERG28, DERA | PTPN7 4868/4885HMGCR 1703/4885RECQL 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.